Karachentsev Y. I., Dubovyk V. M., Gopkalova I. V., Khaziev V. V., Sazonov M. E., Gerasimenko L. V.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

. Surgical treatment of primary hyperparathyroidism (PHPT) is aimed at removing the hormonally active focus – a pathologically changed or adenomatously transformed adenoma (one or more) of the parathyroid gland, but there are very few publications in the literature devoted to studying the long-term results of this treatment. This question became the goal of our research. To evaluate the effectiveness of surgical treatment, we analyzed the long-term results of 45 people who were operated on for PHPT from 2000 to 2020. They were examined in detail, the levels of PTH, vitamin (25(OH)D), total and ionized calcium in the blood were determined , blood phosphorus. The results of the research showed that in the remote period after the operation, no recurrence of primary hyperparathyroidism was detected. However, the examination revealed a deficiency (in 4 cases – 9 %) or insufficiency (in 16 cases – 35.5%) of vitamin (25(OH)D, the indicator of which was 27.24±4.28 ng/ml, and ranged from (6.67 to 65.50) ng/mL. This, in turn, resulted in mild hypercalcemia in 6.7% of patients and hypocalcemia in 9 % of cases. Ionized calcium was more sensitive to decreased vitamin (25(OH)D, therefore, a decrease in its level was detected in 47 % of the examined. The level of PTH was slightly increased in only 5 people (12 %). Thus, the deficiency of vitamin (25(OH)D) led to a decrease in the level of total and ionized calcium in the blood, and a long-term deficiency of vitamin (25(OH)D) caused an increase in the level of parathyroid hormone, which subsequently led to hypercalcemia. Thus, the analysis of long-term results showed that surgical treatment is a radical and effective method of treating patients with primary hyperparathyroidism. But management of patients in the long term after surgery for primary hyperparathyroidism requires monitoring of vitamin D in order to prevent possible relapses of the disease.

surgical treatment of primary hyperparathyroidism,hyperparathyroidism,vitamin D,parathyroid hormone.

1. Obiarinze R, Chen H, Lindeman B, Fazendin J, Ramonell KM. Parathyroid Imaging Practices for Primary Hyperparathyroidism Without Previous Operations Among Endocrine Surgery Program Directors. Am Surg. 2021 May 31;31348211023440. DOI: 10.1177/00031348211023440.
2. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016 Oct 1;151(10):959-968. DOI: 10.1001/jamasurg.2016.2310. 
3. Mokrysheva NG, Eremkina AK, Mirnaya SS, Krupinova JA, Voronkova IA, Kim IV, et al. Klinicheskie rekomendacii po pervichnomu giperparatireozu kratkaya versiya. Problemi Endokrinologi. 2021;67(4):94-124. DOI: 10.14341/probl12801.
4. NICE. Hyperparathyroidism (primary): diagnosis, assessment and initial Management. London: NICE guidelines; 2019. Available from: www.nice.org.uk/guidance/ng132. 
5. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003;7414(327):530-4.
6. Kouvaraki MA, Greer M, Sharma S, Beery D, Armand R, Lee JE, et al. Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery. 2006;139(4):527-34. DOI: 10.1016/j.surg.2005.09.006.
7. Makarov IV, Galkin RA, Prokofeva NA, Boltovskaya VA, Romanov RM, Hohlova DO. Opit diagnostiki i hirurgicheskogo lecheniya pervichnogo giperparatireoza. Endokrinnaya hirurgiya. 2017;11(2):81-89. DOI: 10.14341/serg2017281-89.
8. Seib CD, Meng T, Suh I, Cisco RM, Lin DT, Morris AM, et al. Undertreatment of primary hyperparathyroidism in a privately insured US population: Decreasing utilization of parathyroidectomy despite expanding surgical guidelines. Surgery. 2021;169(1):87-93. DOI: 10.1016/j. surg.2005. 09.006. 
9. Huang SY, Burchette R, Chung J, Haigh PI. Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea. Surgery. 2022;171(1):29-34. DOI: 10.1016/j.surg.2021.03.077.
10. Islam AK. Advances in the diagnosis and the management of primary hyperparathyroidism. Ther Adv Chronic Dis. 2021;12:20406223211015965. DOI: 10.1177/20406223211015965.
11. Elsmark-Svensson H, Rolighed L, Harsløf T, Rejnmark L. Risk of fractures in primary hyperparathyroidism: a systematic review and metaanalysis. Osteoporos Int. 2021;32(6):1053-1060. DOI: 10.1007/s00198-021-05822-9.
12. Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016;19(2):16033. DOI: 10.1038 /nrdp.2016.33.
13. Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J. Clin. Endocrinol. Metab. 2015;100(9):3443-51. DOI: 10.1210/jc.2015-2022.
14. Canaff L, Hendy GN. Human calcium-sensing receptor gene: Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem. 2002;277(33):30337-50. DOI: 10.1074/jbc.M201804200.
15. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. (Oxf). 2005;63(5):506-13. DOI: 10.1111/j.1365- 2265.2005. 02371.x.
16. Battista C, Guarnieri V, Carnevale V, Baorda F, Pileri M, Garrubba M, et al. Vitamin D status in primary hyperparathyroidism: effect of genetic background. Endocrine. 2017;55(1):266-72. DOI: 10.1007/s12020-016-0974-x.
17. Demiralay E. Comparison of proliferative activity in parathyroid glands in primary and secondary hyperparahyroidism. Acta Endocrinol. (Buchar). 2011;7(4):513-22. DOI: 10.4183/aeb.2011.513.
18. Nasser M. Clinical significance of vitamin D deficiency in primary hyperparathyroidism, and safety of vitamin D therapy. South Med. J. 2011 Jan;104(1):29-33. DOI: 10.1097/SMJ.0b013e3181fcd772.
19. Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev. 2008;66(10(2)):116-24. DOI: 10.1111/j.1753- 4887.2008.00094.x.
20. Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, et al. Vitamin D treatment in primary hyperparathyroidism: A randomized placebo controlled trial. J. Clin Endocrinol Metab. 2014;99(3):1072-80. DOI: 10.1210/jc.2013-3978.
21. Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014;80(6):797-803. DOI: 10.1111/cen.12398.

«Bulletin of problems biology and medicine» Issue 4 (167), 2022 year, 160-166 pages, index UDK 616.441, 616.447-008.6:616-07

10.29254/2077-4214-2022-4-167-160-166